Recombinant biglycan promotes bone morphogenetic protein-induced osteogenesis.

Area of Science:

• Biomaterials Science
• Regenerative Medicine
• Craniofacial Surgery

Background:

• Biglycan (BGN) is a small leucine-rich proteoglycan involved in bone formation.
• Tissue-derived BGN positively influences bone morphogenetic protein 2 (BMP-2) activity.
• Investigating recombinant BGN (GST-BGN) lacking posttranslational modifications is crucial for understanding its osteogenic potential.

Purpose of the Study:

• To evaluate the effects of glutathione-S-transferase-fused recombinant biglycan (GST-BGN) on craniofacial bone regeneration.
• To determine if GST-BGN can enhance the osteogenic activity of BMP-2 in vitro and in vivo.

Main Methods:

• In vitro: C2C12 cell culture system to assess BMP-2-induced Smad 1/5/8 phosphorylation and alkaline phosphatase activity with GST-BGN.
• In vivo: Sprague-Dawley rat mandible defect model using varying doses of BMP-2 and GST-BGN.
• Evaluation of bone regeneration using microcomputed tomography and histologic analyses at 2 weeks post-surgery.

Main Results:

• GST-BGN enhanced BMP-2-induced Smad 1/5/8 phosphorylation and alkaline phosphatase activity in C2C12 cells.
• In vivo, suboptimal doses of BMP-2 combined with 4 or 8 µg of GST-BGN resulted in the greatest bone formation within the defect.
• Bone formed with suboptimal BMP-2 and GST-BGN was well-organized compared to optimal BMP-2 alone.

Conclusions:

• Recombinant biglycan (GST-BGN) effectively promotes osteogenesis.
• GST-BGN enhances the efficacy of low-dose BMP-2, suggesting a synergistic effect in promoting bone regeneration.
• GST-BGN holds potential as a therapeutic agent for craniofacial bone regeneration.